Compare Recursion Pharmaceuticals Inc (RXRX) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Zillow Group Inc Class A — how do they compare? Recursion Pharmaceuticals Inc trades at $3.3 (market cap $1.81B), while Zillow Group Inc Class A trades at $33.28 (market cap $7.68B). The key difference: Zillow Group Inc Class A is far larger — about 4.2× Recursion Pharmaceuticals Inc's market cap. Which is the better fit depends on your goals.
| RXRX | ZG | |
|---|---|---|
Market Cap | $1.81B | $7.68B |
Sector | Health | Media |
52-Week High | $6.79 | $86.76 |
52-Week Low | $2.84 | $29.14 |
Enterprise Value | $1.33B | $7.56B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.295, up 0.15% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported a Q2 2026 earnings miss with revenue declining year-over-year, while maintaining a strong cash position from financing activities. Recent news highlights participation in investor conferences and partnership advancements with Genentech.
Outlook remains speculative with high revenue growth potential from AI-driven drug discovery partnerships, but significant risks persist due to deep losses and negative margins. Analyst sentiment is mixed with a 40% buy rating, emphasizing the stock's high-risk, high-reward profile dependent on future clinical and commercial milestones.
Zillow Group (ZG) trades at $32.97, down 3.23% today, reflecting near-term pressure amid a securities class action deadline. The stock shows a bearish technical signal with support at $32 and resistance at $35. Fundamentally, revenue grew to $2.58B in 2025 with a net income of $23M, marking a return to profitability after losses in prior years, though valuation ratios like a P/E of 149 indicate high expectations. Recent Q2 2026 earnings beat expectations with 18% revenue growth, driven by the Preferred Agent model.
The outlook is mixed: analyst consensus is a Buy with a $47.56 price target, suggesting 44% upside, but risks include legal overhangs from the class action and a high P/E requiring sustained growth. Investors should weigh the bullish monetization shift against near-term volatility and profitability challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
